Cash-Strapped Valeant May Sell Salix to Takeda

Source: Wall Street Journal

Nov 02, 2016

Valeant Pharmaceuticals is in advanced talks to sell its Salix stomach-drug business to Japan’s Takeda Pharmaceutical for about $10 billion, says the Wall Street Journal.

Valeant bought the North Carolina-based Salix Pharma in March 2015, for roughty $11B.

If the sale to Takeda goes through, it would enable Valeant to greatly reduce its debt load. Valeant shares jumped after media sources reported on the potential deal, rising 34%

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments